A drug, semaglutide, made by Novo Nordisk, already is marketed as a treatment for Type 2 diabetes. In a clinical trial published in the New England Journal of Medicine, researchers at Northwestern University in Chicago tested semaglutide at a much higher dose as an anti-obesity medication.
Nearly 2,000 participants, at 129 centers in 16 countries, injected themselves weekly with semaglutide or a placebo for 68 weeks. Those who got the drug lost 15 to 20 percent of their body weight, on average, compared.
The most effective treatment so far is bariatric surgery, which helps people lose 25 percent to 30 percent of body weight, on average.
No comments:
Post a Comment